The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHowden Joinery Regulatory News (HWDN)

Share Price Information for Howden Joinery (HWDN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 872.00
Bid: 874.00
Ask: 875.00
Change: 13.50 (1.57%)
Spread: 1.00 (0.114%)
Open: 869.00
High: 880.50
Low: 859.00
Prev. Close: 858.50
HWDN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Howdens CFO Succession

16 Oct 2020 07:00

RNS Number : 2665C
Howden Joinery Group PLC
16 October 2020
 

 

16 October 2020

 

 

Howden Joinery Group Plc

("Howdens")

 

CFO SUCCESSION

Howden Joinery Group Plc today announces that Mark Robson will be moving on from his role as Deputy Chief Executive and Chief Financial Officer (DCEO & CFO) on 26th December 2020, in order to take on a new challenge outside of the Group. He will be succeeded as Chief Financial Officer (CFO) by Paul Hayes, previously CFO of Consort Medical Plc. Paul will join Howdens on 2nd November 2020 and will become an executive director and member of Howdens' Board on 27th December 2020. Having ensured smooth transition through the CEO succession from Matthew Ingle to Andrew Livingston, the Board has reviewed the Group's executive structure and concluded it will revert to a standard structure with CEO and CFO on the Board.

 

Mark Robson joined the Group Board as CFO in April 2005 and was appointed Deputy CEO in May 2014 in addition to his role as CFO. In his early years as CFO he was integral in the restructuring and refinancing of the Group, strengthening its balance sheet whilst ensuring that there was sufficient capital for the Howdens business to grow. During his tenure, the number of Howdens depots has grown from 342 to 759, with turnover increasing from £618m to £1.6bn. During the same period the Group share price has increased from £0.80 to £6.731.

 

Paul Hayes was CFO of Consort Medical Plc, the developer and manufacturer of drugs and premium drug delivery devices, from 2017 until its acquisition by Recipharm AB in February 2020. He has extensive experience in senior finance roles at a number of UK and US listed companies including Vitec Group Plc, Signet Jewelers, RHM Plc and Smiths Group Plc. He is a chartered accountant and qualified with Ernst & Young. 

Richard Pennycook, Chairman of Howdens, commented: "Mark has played a pivotal role, over many years, in building Howdens into the strong, sizeable and successful business it is today. His careful, thoughtful and prudent management of the company's finances has been a key element of our ability to weather the storm of the Covid-19 pandemic. The Board gives heartfelt thanks for his service and he should be proud of his many achievements. On behalf of the Board, I welcome Paul to the Group."

 

Andrew Livingston, CEO said: "Mark has made a very significant contribution to the success of Howdens over the last 15 years and I am especially grateful for his advice, guidance and support since I first joined the business in 2018. I have enjoyed working with him enormously and, together with the whole team at Howdens, wish him the very best for the future.

 

"Paul Hayes comes to the business with a first class record of achievement in consumer and vertically integrated businesses and will, I'm sure, be a great fit with Howdens. I very much look forward to working with him."

 

Paul Hayes will be paid in line with Howden's remuneration policy as approved by shareholders in May 2019. He has no other listed company appointments and has not been a director of any listed company in the previous five years, which would need to be disclosed under LR 9.6.13(1) other than those disclosed above.

 

There is no further information required to be disclosed pursuant to paragraph 9.6.13R of the Listing Rules in respect of Paul Hayes.

 

This announcement is made in accordance with Listing Rules 9.6.11R and 9.6.13 R.

 

 1Depot, turnover and share price figures are as at 31 December 2005 and 31 December 2019.

 

 Enquiries

 Investors/analysts:

 Guy Stainer

 Head of Investor Relations + 44 (0) 20 7535 1164/+44 (0) 7739 778187

 

 Media:

 Citigate

 Simon Rigby/Nick Hayns + 44 (0) 20 3926 8503

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAMABPTMTBBBTM
Date   Source Headline
2nd May 20242:25 pmRNSResult of AGM
2nd May 20249:36 amRNSDirector/PDMR Shareholding
2nd May 20249:00 amRNSAGM Statement
1st May 20249:00 amRNSTotal Voting Rights
30th Apr 20247:00 amRNSTrading Update
22nd Apr 20241:29 pmRNSHolding(s) in Company
19th Apr 20244:10 pmRNSSIP PDMR Notification
15th Apr 20244:32 pmRNSHolding(s) in Company
10th Apr 20245:25 pmRNSHolding(s) in Company
10th Apr 20242:30 pmRNSDirector/PDMR Shareholding
10th Apr 20249:35 amRNSTransfer of Treasury Shares
2nd Apr 20249:00 amRNSTotal Voting Rights
26th Mar 202412:51 pmRNSDirector/PDMR Shareholding
20th Mar 20244:06 pmRNSSIP PDMR Notification
20th Mar 20249:02 amRNSAnnual Report and Accounts and Notice of AGM
20th Mar 20249:00 amRNSAnnual Report and Accounts and Notice of AGM
18th Mar 20245:04 pmRNSHolding(s) in Company
12th Mar 20242:27 pmRNSHolding(s) in Company
12th Mar 20242:09 pmRNSHolding(s) in Company
1st Mar 202411:30 amRNSTotal Voting Rights
29th Feb 20247:00 amRNS2023 Full Year Results
20th Feb 20249:00 amRNSSIP PDMR Notification
1st Feb 20249:00 amRNSBlock listing Interim Review
1st Feb 20249:00 amRNSTotal Voting Rights
19th Jan 20244:17 pmRNSSIP PDMR Notification
2nd Jan 20249:00 amRNSTotal Voting Rights
19th Dec 20233:49 pmRNSSIP PDMR Notification
8th Dec 20235:59 pmRNSDirector/PDMR Shareholding
1st Dec 20239:00 amRNSTotal Voting Rights
24th Nov 202310:00 amRNSChange of Registered Office
21st Nov 20231:07 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:00 amRNSDirector/PDMR Shareholding
3rd Nov 20239:00 amRNSDirectorate Change
2nd Nov 20237:00 amRNSTrading Update
1st Nov 20239:00 amRNSTotal Voting Rights
13th Oct 20234:17 pmRNSHolding(s) in Company
10th Oct 20234:28 pmRNSSIP PDMR Notification
2nd Oct 20239:00 amRNSTotal Voting Rights
26th Sep 20239:48 amRNSHolding(s) in Company
20th Sep 202310:47 amRNSSIP PDMR Notification
1st Sep 20239:00 amRNSTotal Voting Rights
29th Aug 20233:52 pmRNSTransfer of Treasury Shares
29th Aug 202312:28 pmRNSSIP PDMR Notification
21st Aug 202310:01 amRNSSIP PDMR Notification
8th Aug 20235:46 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:25 pmRNSDirector/PDMR Shareholding
1st Aug 20239:01 amRNSBlock listing Interim Review
1st Aug 20239:00 amRNSTotal Voting Rights
20th Jul 202312:15 pmRNSSIP PDMR Notification
20th Jul 20237:00 amRNS2023 Half Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.